Pitcairn Co. trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 5.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,674 shares of the company’s stock after selling 290 shares during the quarter. Pitcairn Co.’s holdings in Axsome Therapeutics were worth $373,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Washington Trust Advisors Inc. bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $26,000. Russell Investments Group Ltd. lifted its position in shares of Axsome Therapeutics by 5,550.0% during the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after acquiring an additional 777 shares during the period. Covestor Ltd lifted its position in shares of Axsome Therapeutics by 54,750.0% during the 1st quarter. Covestor Ltd now owns 1,097 shares of the company’s stock valued at $88,000 after acquiring an additional 1,095 shares during the period. Janiczek Wealth Management LLC bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at $97,000. Finally, SG Americas Securities LLC bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $170,000. 81.49% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, Director Mark Coleman sold 5,249 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total value of $394,777.29. Following the completion of the sale, the director now owns 19,848 shares of the company’s stock, valued at $1,492,768.08. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Mark Coleman sold 5,249 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total transaction of $394,777.29. Following the completion of the sale, the director now owns 19,848 shares of the company’s stock, valued at $1,492,768.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark L. Jacobson sold 7,910 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total value of $587,792.10. Following the sale, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $429,734.73. The disclosure for this sale can be found here. Insiders own 22.40% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Report on Axsome Therapeutics
Axsome Therapeutics Price Performance
AXSM traded up $0.75 on Thursday, reaching $85.98. The stock had a trading volume of 380,774 shares, compared to its average volume of 709,988. Axsome Therapeutics, Inc. has a fifty-two week low of $55.02 and a fifty-two week high of $98.40. The firm has a 50-day moving average of $78.16 and a 200-day moving average of $79.50. The company has a current ratio of 3.20, a quick ratio of 3.09 and a debt-to-equity ratio of 1.25. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of -13.36 and a beta of 1.26.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.11. The company had revenue of $75.00 million during the quarter, compared to analysts’ expectations of $69.91 million. Axsome Therapeutics had a negative return on equity of 87.17% and a negative net margin of 118.07%. As a group, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -4.66 EPS for the current year.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Recommended Stories
- Five stocks we like better than Axsome Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- What is a Special Dividend?
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What is a Dividend King?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.